Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...
Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald initiated coverage of Novavax, Inc. (NASDAQ:NVAX) with an Overweight rating and a ...
Novavax is slimming down again by striking a deal to transfer the lease to its Maryland corporate headquarters to AstraZeneca in exchange for nearly $60 million. The Gaithersburg, Maryland-based ...
Novavax is pushing ahead with plans to slim down with a deal to offload one its locations in Maryland and surrounding property, which is expected to net $60 million in cash for the vaccine maker.
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
GAITHERSBURG, Md., Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European ...
Hosted on MSN
Novavax Transfers EU Vaccine Rights to Sanofi
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Novavax ( (NVAX)) has issued an update.
(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...
Novavax, Inc. receives a Hold rating, reflecting improved prospects after its Sanofi partnership and upgraded 2025 revenue guidance to $1–1.05 billion. The SNY deal provides upfront payments, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback